Conventional biomarkers exhibit fundamental limitations: the CPS neglects spatial heterogeneity, and CPS‐negative patients may still respond to aPD‐1 therapy.[40, 41] While tumor mutational burden (TMB) reflects static genomic metrics rather than dynamic immune evasion.[42] Although CD8+ Texprog cells determine immunotherapy efficacy,[43] targeting them is limited by their irreversible differentiation into Texterm cells during tumor progression.[44, 45] In contrast, our study revealed that the stromal Texterm cell density demonstrates superior predictive power (AUC = 0.86). This evidence concerns the gene CD8A and neoplasm.